Evidence map›Paper›PMID 30476461›Full record

ReviewSexual health2018

Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and emerging models of PrEP implementation.

Patrick S Sullivan, Aaron J Siegler

Registry-linked trialAbstract readReview
In one paragraph

Review in Sexual health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06141408 (A Community-based Intervention to Increase PrEP Initiation in Prince George's County, Maryland), which is not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06141408 narecruitingnot on this mapstarted 2022, after this paper: background citation

A Community-based Intervention to Increase PrEP Initiation in Prince George's County, Maryland: Reducing HIV Stigma and Increasing Social Support

TypeinterventionalSponsorGeorge Mason UniversityRan2022 to 2026Enrolled120ConditionsHiv, Mental Health Issue, Support, FamilyArmsMPowerment PrEP Promotion Intervention
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Perceptions of DoxyPEP use Among Racial & Ethnic Minority Patients.Journal of racial and ethnic health disparities · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Retention of clients in HIV oral pre-exposure prophylaxis care in Engela, Namibia.African journal of primary health care & family medicine · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Patrick S SullivanDepartment of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA.
Aaron J SieglerDepartment of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA.

Funding

Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuumU19HD089881 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIGHTOW-WEIDMAN, LISA B, SULLIVAN, PATRICK SEAN · 2016 to 2022
$35.8M
Making it last: A randomized, controlled trial of a home care system to promote persistence in PrEP careR01MH114692 · NIMH · EMORY UNIVERSITY · PI MAYER, KENNETH H, SIEGLER, AARON JULIUS · 2017 to 2021
$5.8M
Understanding substance use and incident HIV/STI among young black MSMR01DA038196 · NIDA · EMORY UNIVERSITY · PI ROSENBERG, ELI SAMUEL, SULLIVAN, PATRICK SEAN · 2014 to 2018
$3.2M
NCHHSTP CDC HHS U01 PS004977NIAID NIH HHS P30 AI050409NICHD NIH HHS U19 HD089881NIDA NIH HHS R01 DA038196NIMH NIH HHS R01 MH114692
6 · The paper itself

Abstract

Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) is now accepted as an efficacious approach to preventing HIV acquisition among people at high risk of HIV infection but, in most places, PrEP uptake to date has not been sufficient to have a large effect on HIV incidence. In this paper we consider several key elements of the effort to expand PrEP uptake for at-risk populations who would benefit most, such as increasing access to PrEP, integrating PrEP programs with other services, promoting PrEP persistence and developing systems for monitoring PrEP use. We used a PrEP Continuum framework to describe barriers to equitable uptake of PrEP, and to illustrate possible solutions to barriers. Access to PrEP includes regulatory issues and geographic proximity to PrEP providers. Integrating PrEP programs with other comprehensive sexual health services, through clinic-based programs or technology-based approaches, offers opportunities to identify PrEP candidates and improve linkages to PrEP care. Once at-risk people are prescribed PrEP, lowering barriers to persistence on PrEP is critical to realising the most population benefits. To understand progress and identify underserved groups and communities, systems to monitor the uptake of PrEP are needed. Making the most of a new biomedical intervention tool requires ongoing research about implementation, scale-up through multiple channels, including community-based organisations, and high-quality monitoring of uptake. We must turn to questions of PrEP implementation and continue to seek innovative approaches to reduce barriers to PrEP uptake and persistence on PrEP.

Indexed as

Health EquityHealth Services AccessibilityPre-Exposure ProphylaxisAdministration, OralAnti-HIV AgentsEmtricitabineHIV InfectionsHumansTenofovirAnti-HIV AgentsEmtricitabineTenofovir

Identifiers

PMID30476461
PMCPMC6506265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.